As one of the most important pathological types of lung cancer, in recent years, individualized lung adenocarcinoma treatments, including EGFR TKIs and EML4‐ALK, have been highly effective for the treatment of patients with EGFR mutations or harboring EML4‐ALK fusions.3, 4. This evidence concerns the gene EGFR and lung carcinoma.